Fig. 5

Prosurvival PERK/NRF2/HO-1 activation in KG1 LSC-like cells upon G9a inhibition. a, NRF2 and HO-1 expression, analyzed by western blotting, after cell treatment with various concentrations of BIX-01294 for 24 h. b, NRF2 and HO-1 expression, analyzed by western blotting, after cell treatment with BIX-01294 (10 μmol/L) for different periods. c, Protein expression, analyzed by western blotting with the indicated antibodies, in PERK siRNA-transfected and non-transfected cells after treatment with BIX-01294 (15 μmol/L) for 48 h. d, Protein expression, analyzed by western blotting with the indicated antibodies, in NRF2 siRNA-transfected and non-transfected cells after treatment with BIX-01294 (10 μmol/L) for 48 h. e, Apoptotic fractions, measured using flow cytometry, after cell treatment with BIX-01294 (10 μmol/L) in the absence or presence of the NRF2 inhibitor brusatol (0.5 μmol/L) for 48 h. f, Apoptosis levels, determined by flow cytometry, after treatment of NRF2 siRNA- or control siRNA-transfected cells with different concentrations of BIX-01294 for 48 h